Eli Lilly and Company $LLY Shares Sold by MTM Investment Management LLC

MTM Investment Management LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 6.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 9,054 shares of the company’s stock after selling 602 shares during the quarter. Eli Lilly and Company comprises about 3.1% of MTM Investment Management LLC’s portfolio, making the stock its 4th largest position. MTM Investment Management LLC’s holdings in Eli Lilly and Company were worth $9,730,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Fidelis Capital Partners LLC lifted its position in Eli Lilly and Company by 2.1% during the 4th quarter. Fidelis Capital Partners LLC now owns 8,340 shares of the company’s stock worth $8,962,000 after acquiring an additional 171 shares during the period. Knights of Columbus Asset Advisors LLC lifted its position in Eli Lilly and Company by 58.4% during the 4th quarter. Knights of Columbus Asset Advisors LLC now owns 616 shares of the company’s stock worth $662,000 after acquiring an additional 227 shares during the period. King Luther Capital Management Corp lifted its position in Eli Lilly and Company by 3.1% during the 4th quarter. King Luther Capital Management Corp now owns 191,416 shares of the company’s stock worth $205,711,000 after acquiring an additional 5,761 shares during the period. ICW Investment Advisors LLC lifted its position in Eli Lilly and Company by 459.1% during the 4th quarter. ICW Investment Advisors LLC now owns 5,652 shares of the company’s stock worth $6,074,000 after acquiring an additional 4,641 shares during the period. Finally, Expressive Wealth LLC acquired a new stake in Eli Lilly and Company during the 4th quarter worth about $721,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Jefferies Financial Group lifted their price target on Eli Lilly and Company from $1,300.00 to $1,330.00 in a research report on Thursday, May 21st. CICC Research lifted their price target on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 11th. Bank of America lifted their price target on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a research report on Tuesday. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Tuesday, March 10th. Finally, Guggenheim reaffirmed a “buy” rating and set a $1,183.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, May 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,227.00.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly announced agreements to acquire Curevo, LimmaTech Biologics, and Vaccine Company in a combined deal worth up to $3.83 billion, expanding its vaccine and infectious-disease pipeline. Lilly announces three acquisitions to build infectious disease portfolio
• Positive Sentiment: The acquisition spree is being viewed as a strategic move to diversify Lilly’s business and leverage the cash flow generated by its obesity franchise into adjacent high-value markets. Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
• Positive Sentiment: LLY has also been hitting record highs and became the first pharmaceutical company valued at $1 trillion, reinforcing the market’s confidence in its growth story. Eli Lilly Stock Hits Record Highs, Becomes First Pharmaceutical Firm Worth $1 Trillion
• Neutral Sentiment: Additional coverage highlighted continued investor attention around Lilly’s momentum, analyst optimism, and its participation in a Goldman Sachs healthcare conference, but these items are less likely to move the stock on their own. Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
• Neutral Sentiment: Articles comparing Lilly with Novo Nordisk and discussing Trump’s stock purchases do not appear to change the core investment thesis, with Lilly’s fundamentals still seen as the main driver. President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too?
• Neutral Sentiment: Competition concerns around Novo Nordisk in the obesity-pill market were framed as manageable rather than a major threat. Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried?

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,085.36 on Thursday. The stock has a market cap of $1.02 trillion, a PE ratio of 38.56, a price-to-earnings-growth ratio of 1.16 and a beta of 0.48. The business has a 50-day simple moving average of $948.23 and a 200-day simple moving average of $1,007.67. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 35.82 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company’s payout ratio is 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.